Stockscreener 앱 받기
54.87
1.05%
0.57
시장 영업 전:
56.40
1.53
+2.79%
전일 마감가:
$54.30
열려 있는:
$55.055
하루 거래량:
10.30M
Relative Volume:
0.67
시가총액:
$186.02B
수익:
$45.44B
순이익/손실:
$16.18B
주가수익비율:
15.10
EPS:
3.634
순현금흐름:
$9.21B
1주 성능:
-0.65%
1개월 성능:
+10.22%
6개월 성능:
-26.63%
1년 성능:
-59.85%
1일 변동 폭
$54.33
$55.20
1주일 범위
$52.72
$55.23
52주 변동 폭
$45.05
$138.22
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
54.87 | 241.59B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Is the Market Bullish or Bearish on Novo Nordisk? - Sahm
This Under-the-Radar Healthcare Stock Could Soar in 2026 - The Motley Fool
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - GlobeNewswire Inc.
Emmy Award Success for Passion and Robert Valleys 400 Boys Episode in Netflixs Love, Death and Robots - DLH.net
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize
NVO’s Debt-to-Equity Ratio at 0.59: What It Means for Novo Nordisk ADR’s Future - investchronicle.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - GlobeNewswire Inc.
Novo Nordisk A/S Class Action Lawsuit: Pomerantz Law Firm Reminds Investors of Upcoming Deadlines - AInvest
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Using data models to predict Novo Nordisk A s (b Shares) Adrhedged stock movementBuy Signal & Weekly Stock Performance Updates - Newser
Reversal indicators forming on Novo Nordisk A s (b Shares) Adrhedged stockJuly 2025 Action & Daily Growth Stock Investment Tips - Newser
Can momentum traders help lift Novo Nordisk A s (b Shares) Adrhedged2025 Stock Rankings & Long-Term Safe Investment Plans - Newser
Is Novo Nordisk A s (b Shares) Adrhedged showing signs of accumulationJuly 2025 Institutional & Low Risk Entry Point Tips - Newser
Is Novo Nordisk A s (b Shares) Adrhedged still worth holding after the dipTrade Risk Assessment & Consistent Growth Equity Picks - Newser
Does Novo Nordisk A s (b Shares) Adrhedged fit your quant trading modelMarket Trend Summary & Detailed Earnings Play Alerts - Newser
Is Novo Nordisk A s (b Shares) Adrhedged stock ready for a breakoutMarket Risk Report & Verified Short-Term Plans - Newser
What moving averages say about Novo Nordisk A s (b Shares) Adrhedged2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What’s next for Novo Nordisk A s (b Shares) Adrhedged stock priceEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedChart Signals & Precise Entry and Exit Recommendations - Newser
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.75%
자본화:
|
볼륨(24시간):